CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, November 21, 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (8 pages) |